I agree that this site is using cookies. You can find further informations here.
X
Fabbro, M
~ 1300  results:
Search for persons X
?
1

34O ROCSAN: A multicentric randomized phase II/III evaluati..:

Ray-Coquard, I.L. ; Bellesoeur, A. ; Fabbro, M....
ESMO Open.  9 (2024)  - p. 103534 , 2024
Link: https://doi.org/10.1016/..
 
?
2

41MO ESR1 mutation in untreated endometrial cancer: Prevale..:

Blanc-Durand, F. ; Nikolaev, S. ; Leman, R....
ESMO Open.  9 (2024)  - p. 103541 , 2024
Link: https://doi.org/10.1016/..
 
?
3

P-567 Is mosaic embryo transfer a valid alternative for pat..:

Galain, M ; Caviglia, E ; Diaz, Y...
Human Reproduction.  39 (2024)  Supplement_1 - p. , 2024
Link: https://doi.org/10.1093/..
 
?
4

Long term activity of vemurafenib in cancers with BRAF muta..:

Blay, J.Y. ; Cropet, C. ; Mansard, S....
ESMO Open.  8 (2023)  6 - p. 102038 , 2023
Link: https://doi.org/10.1016/..
 
?
5

59P Expression of CD47 a potent 'don't eat me signal' in ov..:

Chardin, L. ; Yaniz Galende, E. ; Genestie, C....
ESMO Open.  8 (2023)  1 - p. 100839 , 2023
Link: https://doi.org/10.1016/..
 
?
6

EE608 Cost Effectiveness Analysis of a Large (Foundation Me..:

Perrier, L ; Tredan, O ; Morelle, M...
Value in Health.  25 (2022)  12 - p. S175 , 2022
Link: https://doi.org/10.1016/..
 
?
7

EE189 Cost-Effectiveness Analyses of Lung Cancer Screening ..:

Fabbro, M ; Hahn, K ; Novaes, O..
Value in Health.  25 (2022)  12 - p. S90 , 2022
Link: https://doi.org/10.1016/..
 
?
8

P11.19.B Bevacizumab in recurrent WHO grade 2-3 gliomas:

Annakib, S ; Rigau, V ; Darlix, A...
Neuro-Oncology.  24 (2022)  Supplement_2 - p. ii60-ii60 , 2022
Link: https://doi.org/10.1093/..
 
?
9

EE493 Cost-Effectiveness of Pembrolizumab+Lenvatinib for Tr..:

Fabbro, M ; Cagnan, L ; Midy, F...
Value in Health.  25 (2022)  12 - p. S152-S153 , 2022
Link: https://doi.org/10.1016/..
 
?
10

P01.15.A Longitudinal assessment of neurocognition and qual..:

Darlix, A ; Fabbro, M ; Monnier, M...
Neuro-Oncology.  24 (2022)  Supplement_2 - p. ii27-ii27 , 2022
Link: https://doi.org/10.1093/..
 
?
11

Need for risk-adapted therapy for malignant ovarian germ ce..:

Derquin, F. ; Floquet, A. ; Hardy-Bessard, A.C....
Gynecologic Oncology.  158 (2020)  3 - p. 666-672 , 2020
Link: https://doi.org/10.1016/..
 
?
12

Time without symptoms or toxicity in patients with recurren..:

Matulonis, U.A. ; Walder, L. ; Nøttrup, T.J....
Gynecologic Oncology.  154 (2019)  - p. 2 , 2019
Link: https://doi.org/10.1016/..
 
?
13

P04.02 Postponing the medical treatment is possible in sele..:

Darlix, A ; Rigau, V ; Fraisse, J...
Neuro-Oncology.  21 (2019)  Supplement_3 - p. iii28-iii29 , 2019
Link: https://doi.org/10.1093/..
 
?
14

P14.73 Toxicity and outcomes of reduced-dose whole brain ra..:

Lesueur, P ; Damaj, G ; Hoang-Xuan, K...
Neuro-Oncology.  21 (2019)  Supplement_3 - p. iii84-iii85 , 2019
Link: https://doi.org/10.1093/..
 
?
15

Is mitochondrial DNA (MTDNA) quantification a potential bio..:

Bilinski, M. ; Lorenzi, D. ; Fabbro, M....
Fertility and Sterility.  110 (2018)  4 - p. e421 , 2018
Link: https://doi.org/10.1016/..
 
1-15